ArticleBiology2021
Butyrate Alleviates Cytokine-Induced Barrier Dysfunction by Modifying Claudin-2 Levels.
Article in Biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 61 citations in OpenAlex.
- Trial
- Current evidence and emerging therapeutic strategies for non-exercise interventions in sarcopenia associated with chronic obstructive pulmonary disease: a narrative review.Journal of thoracic disease · 2026Review
- A Novel Mixture ContainingInternational journal of molecular sciences · 2026Article
- Psychiatric Symptoms Associated with Non-Celiac Gluten Sensitivity: A Focused Narrative Review.Nutrients · 2026Review
- Panaxynol mitigates chemotherapy-induced intestinal mucositis by improving the colonic microenvironment in murine models.American journal of physiology. Gastrointestinal and liver physiology · 2026Article
- Metabolite mimicry identifies butyrate analogs with select protective functions in the intestinal mucosa.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Betanin ameliorates dextran sulfate sodium-induced colitis in mice by modulating tight junction protein expression.Biochemistry and biophysics reports · 2026Article
- Cranberry extract-supplemented microbiota effluents enhance intestinal barrier integrity via mucin production and antimicrobial activity in murine organoids.Scientific reports · 2026Article
- Lipid-derived microbial metabolites at the gut-liver interface: regulation of intestinal barrier function, immune signaling, and metabolic inflammation.Frontiers in physiology · 2026Review
- Dietary polysaccharides in the management of inflammatory bowel disease: recent advances.Frontiers in nutrition · 2026Review
- Long-term endurance exercise influences exercise capacity in mice through modulation of the intestinal microbiota by fecal microbiota transplantation.Frontiers in microbiology · 2026Article
- Microbial SCFAs as epigenetic mediators: fine-tuning the gut-brain axis in neurodegenerative disorders.Current research in microbial sciences · 2026Review
- The microbiota-metabolite-immune axis in the olfactory cleft microenvironment: mechanisms and therapeutic implications for dysbiosis-driven olfactory dysfunction in chronic rhinosinusitis.Frontiers in immunology · 2026Review
- Heat stress-induced gut dysbiosis and multi-organ injury: mechanisms and therapeutic modulation.Frontiers in cellular and infection microbiology · 2026Review
- Gut microbiota dysbiosis in sepsis and sepsis-associated organ injury: mechanisms, gut-organ axes, and therapeutic strategies.Frontiers in microbiology · 2026Review
- Butyrate prevents chemotherapy-induced gastrointestinal toxicity and microbial dysbiosis.Scientific reports · 2025Article
- Altered gut microbial functional pathways in people with irritable bowel syndrome enable precision health insights.BMC gastroenterology · 2025Article
- Efficacy of non-psychotropic Cannabis sativa L. standardized extracts in a model of intestinal inflammation.Journal of cannabis research · 2025Article
- The Role of Gut Microbiota in Modulating Immune Signaling Pathways in Autoimmune Diseases.Neuromolecular medicine · 2025Review
- Butyrate Modulates Intestinal Microbiome and Epithelial Function to Attenuate Irinotecan-induced GI Toxicity.Research square · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal (GI) disorders such as celiac disease and inflammatory bowel disease are attributed to intestinal barrier disruption. Imbalance of cytokines has been reported in the intestinal epithelium of patients with GI disorders. Short-chain fatty acids (SCFAs), derived from the fermentation of dietary fiber in the intestine, have been reported to benefit the intestinal barrier. Accordingly, we evaluated the effect of specific SCFAs on intestinal barrier function under cytokine-stimulated conditions. Caco-2 cells were cultured on insert membranes to generate monolayers, which then were used to investigate the effects of SCFAs. Tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), or interleukin-13 (IL-13) was added to the basolateral side of the membrane while SCFAs were added to the apical side. After a 24 h stimulation, transepithelial electrical resistance (TEER) was measured, and the protein levels of claudin-1, claudin-2, claudin-3, claudin-4, occludin, and zonula occludens-1 (ZO-1) were evaluated by Western blot. Butyrate, but not acetate, propionate, or succinate, ameliorated the TNF-α/IFN-γ-induced decrease in TEER. TNF-α/IFN-γ stimulation significantly increased the protein level of claudin-2 and decreased the level of claudin-3. Butyrate significantly attenuated the upregulation of claudin-2 induced by TNF-α/IFN-γ. Butyrate blocked the decrease in TEER and the upregulation of claudin-2 induced by IL-13 without changing the level of other tight junction proteins. Our results suggested that butyrate is the main component of SCFAs to alleviate barrier dysfunction and that claudin-2 is the major target of this SCFA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.